Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.1947.02880170014004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between abnormal systemic coagulation inflammation index and recurrence of deep venous thrombosis as well as quality of life: A retrospective study.
Phlebology
January 2025
Department of Clinical Laboratory, The Second Hospital Affiliated Fujian Medical University, Quanzhou, China.
Background: Deep vein thrombosis (DVT) of the lower limb is a significant clinical challenge with the potential for recurrence, which can lead to increased morbidity and reduced quality of life.
Methods: A retrospective case-control study was conducted involving 367 patients diagnosed with lower limb DVT from June 2020 to June 2023. Patients were categorized into a recurrence group ( = 121) and a non-recurrence group ( = 246) based on DVT occurrence.
Artificial intelligence in thrombosis: transformative potential and emerging challenges.
Thromb J
January 2025
College of engineering and computer sciences, Jazan University, Jazan, Saudi Arabia.
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), continues to pose significant clinical challenges despite advancements in medical care. Artificial intelligence (AI) presents promising opportunities to enhance the diagnosis, prediction, and management of VTE. This review examines the transformative potential of AI in thrombosis care, highlighting both the potential benefits and the challenges that need to be addressed.
View Article and Find Full Text PDFThe Cerebral Venous Disorders Severity Scale.
J Neurointerv Surg
January 2025
Department of Neurointerventional Surgery, Queen's Medical Center, Honolulu, Hawaii, USA.
Treatment of Venous Thromboembolism with Edoxaban over 18 Months: Results from ETNA-VTE Europe.
Thromb Haemost
January 2025
Guy's and St Thomas' NHS Foundation Trust, King's College London, United Kingdom.
Background: The benefits and risks of extending anticoagulant treatment beyond the first 3 to 6 months in patients with venous thromboembolism (VTE) in clinical practice are not well understood.
Methods: ETNA-VTE Europe is a prospective, noninterventional, post-authorization study in unselected patients with VTE treated with edoxaban in eight European countries for up to 18 months. Recurrent VTE, major bleeding, and all-cause death were the primary study outcomes.
Insights into VTE risk in trauma patients: an observational study in an Irish trauma patient population.
Ir J Med Sci
January 2025
School of Pharmacy and Biomolecular Sciences (PBS), Royal College of Surgeons in Ireland, Dublin 2, Ireland.
Background: The rate of VTE in trauma patients varies significantly in the reported literature. We aimed to determine the incidence of VTE in trauma patients in a trauma-receiving hospital over a 7-year period. We sought to evaluate the timing and nature of VTE events and explore the patterns of co-occurrence between PE and DVT, while factoring in clinical care and death outcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!